Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
ORGANIZATION
Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 1
Yoshiaki Kamoya, chairman of the Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) NHI drug pricing study committee, represents drug makers on the Central Social Insurance Medical Council’s (Chuikyo) drug pricing subcommittee. He said at a press conference in June…
To read the full story
Related Article
- Drug Pricing Tomorrow: Full Interview with JMA Vice President Nakagawa
October 5, 2015
- Drug Pricing Tomorrow: JMA’s Nakagawa Says Price Maintenance Premium Should Continue as Trial Measure
September 29, 2015
- Drug Pricing Tomorrow: Full Interview with MOF Budget Examiner Unami
September 25, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 2
September 10, 2015
- Drug Pricing Tomorrow: MOF Budget Examiner Eyes “Sharp Price Cuts” for Both New and Listed Generics in 2016
September 9, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 1
September 9, 2015
- Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 2
September 8, 2015
- Drug Pricing Tomorrow: MHLW Councilor Takeda Says NHI Drug Prices Should Mirror Evaluation of Individual Firms
August 24, 2015
- Drug Pricing Tomorrow: Full Interview with JPA Executive Director Abe
August 13, 2015
- Drug Pricing Tomorrow: FPMAJ’s Kamoya Says Innovation Premium Meant to Head Off Future Drug Lags
August 10, 2015
- Drug Pricing Tomorrow: JPA’s Abe Eyes Longer-Term Trial for Key Pricing Premium
July 28, 2015
- Drug Pricing Tomorrow: Full Interview with Kenporen Vice President Shirakawa
July 24, 2015
- Drug Pricing Tomorrow: Kenporen Veep Wants Holistic Drug Policy in FY2016 Reform
July 15, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 2
July 15, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 1
July 8, 2015
- Drug Pricing Tomorrow: Full Interview with Ex-Chuikyo Chairman Endo
July 2, 2015
- Drug Pricing Tomorrow: MHLW’s Jo Says Price-Maintenance Premium Crucial as Post-Launch Reward for Innovation
June 29, 2015
- Drug Pricing Tomorrow: Ex-Chuikyo Chair Urges Pharma to Look at How to Refine Premium, Not Permanent Introduction
June 25, 2015
ORGANIZATION
- JPWA Reports No Damage from PHP Vulnerability, Renews “No” to FY2027 Revision
October 23, 2026
- Ex-JMA Vice President, Lawmaker Hanyuda Remembered at Memorial Service
October 21, 2026
- Japan Generics Society Calls for Risk-Based Nitrosamine Controls
October 16, 2026
- Japan Expert Calls for Earlier Access to Anti-Obesity Drugs
October 16, 2026
- Japan Falling Behind US, China in Pharma Innovation, EFPIA Chief Urges Action
October 15, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…